Joanne M. Jeter,
MD
Languages Spoken: English
Joanne Jeter, MD, MS.
Associate Professor of Medicine in the Division of Oncology
Medical Director of the Family Cancer Assessment Clinic.
Huntsman Cancer Institute
Sugarhouse Health Clinic
Joanne Jeter, MD, MS, is the Medical Director of the Family Cancer Assessment Clinic and an Associate Professor of Medicine in the Division of Oncology at Huntsman Cancer Institute. She is board-certified in Medical Oncology. After receiving her medical degree at the University of Texas Health Sciences Center in Houston, Texas, she earned a Master of Science degree in Clinical Trials Design and Statistical Analysis from the University of Michigan. She completed her Internal Medicine residency at the University of Alabama-Birmingham and her Medical Oncology fellowship at the University of Michigan. She has authored numerous scientific publications and has been an invited lecturer at over 100 academic seminars, medical conferences, and symposia presenting on multiple topics in cancer genetics, breast cancer, melanoma, and other skin cancers. Her research has been funded by the National Cancer Institute and the American Society of Clinical Oncology, as well as industry sources. She received the Coltman Fellowship from the Southwest Oncology Group, as well as a Merit Award from the National Institutes of Health. She currently serves on the National Cancer Institute's PDQ Cancer Genetics Editorial Board and the American Society of Clinical Oncology's Scientific Program Committee.
Her primary research interest is in personalized chemoprevention for individuals at hereditary risk of cancer. She is passionate about improving education in cancer genetics and finding new means to provide access for genetic counseling and testing, as well as medical care for those with hereditary cancer syndromes. She also takes care of patients with advanced cutaneous malignancies in her medical oncology clinic. In her spare time, she enjoys reading, geocaching, and travel when public health conditions allow it.
Clinical Locations
Clinic 2E, Family Cancer Assessment Clinic
Clinic 2C, Dermatology/Melanoma
801-581-2000
Specialties
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Associate Professor (Clinical) |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Sub: Medical Oncology) National Board of Medical Examiners |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.8/ 5
Care provider's explanation of condition/problem
4.8/ 5
Care provider's effort to include me in decisions
4.8/ 5
Wait time at clinic
4.6/ 5
Care provider's concern for questions & worries
4.8/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
November 07, 2022
Huntsman Cancer Institute
Dr. Jeter is SO smart. She and her team are great. You are in good hands.
UofU Patient
November 03, 2022
Huntsman Cancer Institute
The Doc is always considerate of patients concern & solicits input as a result.
UofU Patient
September 25, 2022
HUNTSMAN CANCER CENTER
Good
UofU Patient
September 19, 2022
HUNTSMAN CANCER CENTER
Dr. Jeter was fantastic. She was personable and professional. She listed carefully to my concerns and answered questions patiently. She definitely included me in decision-making.
UofU Patient
September 04, 2022
HUNTSMAN CANCER CENTER
Love susie because she just makes my visit so friendly and caring. Dr jeter is communicative and caring and on top of everything.
UofU Patient
September 04, 2022
HUNTSMAN CANCER CENTER
Explained everything and listened to my husband , son and I
UofU Patient
August 02, 2022
HUNTSMAN CANCER CENTER
I like Dr Jeter very much. She's a great listener, she fully understands my health issues, and she's very supportive. She offers helpful recommendations for treating my current issues, and she's a very kind, competent physician. I'm very thankful to have her as part of my medical team.
UofU Patient
June 05, 2022
HUNTSMAN CANCER CENTER
The doctor has always been good about including the patient in decisions regarding care after a thorough discussion of treatments and outcomes.
UofU Patient
May 10, 2022
HUNTSMAN CANCER CENTER
The Doctor told me what to do over the initial virtual visit but didn't put in the notes for me which tests I needed to talk to my other doctors about having done and now I can't remember the names of the tests. I've since gone back to look at the visit notes and there's nothing listed as a reference point which I'm supposed to have specific testing done to use for calling in appointments.
UofU Patient
April 04, 2022
HUNTSMAN CANCER CENTER
This experience was amazing. The staff was ver helpful. All of my questions and concerns were finally answered. I didn't feel like I was being rushed through my appointment. I really appreciated the time they took with me.
UofU Patient
April 03, 2022
HUNTSMAN CANCER CENTER
My melanoma team, dr jeter, susan and sometimes jordan the pharmacist gather to ask questions about how I feel and also explain their part of this process. They relax me and make me feel confident..which is like a gift to me. I cherish them as the most unexpected problems have caused the greatest alarm. They calm my shattered nerves. They answer my calls and always answer " my chart "questions. Thank You!
UofU Patient
March 29, 2022
HUNTSMAN CANCER CENTER
I like Dr Jeter very much, she's a great listener, she's knowledgeable and concerned, she's kind and supportive, and she includes me in my treatment decisions. She's a great doctor.
UofU Patient
March 06, 2022
HUNTSMAN CANCER CENTER
Have already referred several people
UofU Patient
February 24, 2022
HUNTSMAN CANCER CENTER
Still no conversation about previous treatment reaction. No discussion about future treatment plans, just will keep an eye on it!
UofU Patient
January 04, 2022
HUNTSMAN CANCER CENTER
I couldn't ask for better careeveryone involved is so special
UofU Patient
December 29, 2021
HUNTSMAN CANCER CENTER
Everything was good
UofU Patient
December 19, 2021
HUNTSMAN CANCER CENTER
Wonderful experience with everything and every person at Huntsman.
UofU Patient
December 05, 2021
HUNTSMAN CANCER CENTER
Dr Jeter is a very good Doctor. Very lucky to have her looking after me. I know I m in very good hands.
UofU Patient
November 24, 2021
HUNTSMAN CANCER CENTER
Provider did not discuss prior or future care or treatments.
UofU Patient
November 23, 2021
HUNTSMAN CANCER CENTER
It was a pleasure meeting Dr. Jeter. She is kind, caring, concerned, and a great listener. She's very knowledgeable about my health concerns and she included me in decisions regarding proposed treatment. I feel complete confidence in her ability to manage my care. Huntsman is very lucky to have her. I look forward to working with her in matters pertaining to my medical issues.
UofU Patient
November 07, 2021
HUNTSMAN CANCER CENTER
Dr Jeter is really great. Lucky to have her as my doctor.
UofU Patient
October 25, 2021
HUNTSMAN CANCER CENTER
Inclusive, caring, hugely knowledgeable.
UofU Patient
October 21, 2021
HUNTSMAN CANCER CENTER
I feel like this visit, since it was just a follow us, could have been over the phone or maybe a zoom call. I wasn't having any issues/concerns and I didn't need blood work that it was unnecessary for me to go all the way there.
UofU Patient
October 18, 2021
HUNTSMAN CANCER CENTER
Dr Jeter is the best
UofU Patient
October 17, 2021
HUNTSMAN CANCER CENTER
Couldn't ask for more. Just top notch!
UofU Patient
October 12, 2021
HUNTSMAN CANCER CENTER
More scans are needed, my attitude is difficult , don't trust a lot
UofU Patient
October 12, 2021
HUNTSMAN CANCER CENTER
Tried to inform me, very good even showing me a diagram
UofU Patient
October 04, 2021
HUNTSMAN CANCER CENTER
I have family members with same disease and I will share my experiences with them.
UofU Patient
September 11, 2021
HUNTSMAN CANCER CENTER
Dr. Jeter is very kind, compassionate and personable. She is super smart and very thorough. She is the best melanoma doc I've had. I am so grateful that she's my doc.
Joanne Jeter, MD, MS.
Associate Professor of Medicine in the Division of Oncology
Medical Director of the Family Cancer Assessment Clinic.
Huntsman Cancer Institute
Sugarhouse Health Clinic
Joanne Jeter, MD, MS, is the Medical Director of the Family Cancer Assessment Clinic and an Associate Professor of Medicine in the Division of Oncology at Huntsman Cancer Institute. She is board-certified in Medical Oncology. After receiving her medical degree at the University of Texas Health Sciences Center in Houston, Texas, she earned a Master of Science degree in Clinical Trials Design and Statistical Analysis from the University of Michigan. She completed her Internal Medicine residency at the University of Alabama-Birmingham and her Medical Oncology fellowship at the University of Michigan. She has authored numerous scientific publications and has been an invited lecturer at over 100 academic seminars, medical conferences, and symposia presenting on multiple topics in cancer genetics, breast cancer, melanoma, and other skin cancers. Her research has been funded by the National Cancer Institute and the American Society of Clinical Oncology, as well as industry sources. She received the Coltman Fellowship from the Southwest Oncology Group, as well as a Merit Award from the National Institutes of Health. She currently serves on the National Cancer Institute's PDQ Cancer Genetics Editorial Board and the American Society of Clinical Oncology's Scientific Program Committee.
Her primary research interest is in personalized chemoprevention for individuals at hereditary risk of cancer. She is passionate about improving education in cancer genetics and finding new means to provide access for genetic counseling and testing, as well as medical care for those with hereditary cancer syndromes. She also takes care of patients with advanced cutaneous malignancies in her medical oncology clinic. In her spare time, she enjoys reading, geocaching, and travel when public health conditions allow it.
Academic Locations
Huntsman Cancer Hospital
801-585-0255
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Associate Professor (Clinical) |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Sub: Medical Oncology) National Board of Medical Examiners |
Education History
| Graduate Training | University of Michigan Clinical Trials Design and Statistical Analysis M.S., 2005 |
| Fellowship | University of Michigan Medical School Fellow, 2005 |
| Residency | University of Alabama at Birmingham School of Medicine Resident, 2002 |
| Internship | University of Alabama at Birmingham School of Medicine Intern, 2000 |
| Professional Medical | University of Texas Health Sciences Center at Houston Medicine M.D., 1999 |
| Undergraduate | Rice University English B.A., 1994 |
Selected Publications - Journal Articles
Journal Article
- Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gershenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G, Melanoma Research Foundation (2021). The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res, 27(10), 2678-2697.
- Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM (2020). Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol, 156(9), 1004-1011.
- Ladd MK, Peshkin BN, Senter L, Baldinger S, Isaacs C, Segal H, Philip S, Phillips C, Shane K, Martin A, Weinstein V, Pilarski R, Jeter J, Sweet K, Hatten B, Wurtmann EJ, Phippen S, Bro D, Schwartz MD (2018). Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer. Transl Behav Med, 10(2), 337-346.
- Boru G, Grosel TW, Pilarski R, Stautberg M, Massengill JB, Jeter J, Singh A, Marino MJ, McElroy JP, Davidorf FH, Cebulla CM, Abdel-Rahman MH (2019). Germline large deletion of BAP1 and decreased expression in non-tumor choroid in uveal melanoma patients with high risk for inherited cancer. Genes Chromosomes Cancer, 58(9), 650-656.
- Garcia A, Frahm C, Jeter JM, Abraham I, Chambers SK, Cragun JM, McBride A (2019). Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations. J Adv Pract Oncol, 10(5), 428-439.
- Oh M, Alkhushaym N, Fallatah S, Althagafi A, Aljadeed R, Alsowaida Y, Jeter J, Martin JR, Babiker HM, McBride A, Abraham I (2019). The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate, 79(8), 880-895.
- Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Meyskens FL Jr, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB (2018). Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer, 125(1), 18-44.
- Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, Jeter J, Abraham I (2017). BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis. J Natl Cancer Inst, 110(11), 1178-1189.
- Cuellar LE, Anampa-Guzmn A, Holgun AM, Velarde J, Portillo-Alvarez D, Zuiga-Ninaquispe MA, Luna-Reyes ER, Vsquez J, Jeter JM, Winkfield KM (2018). Prognostic factors in HIV-positive patients with non-Hodgkin lymphoma: a Peruvian experience. Infect Agent Cancer, 13, 27.
- Pulluri B, Kumar A, Shaheen M, Jeter J, Sundararajan S (2017). Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance. Pharmacol Res, 123, 95-102.
- Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W 3rd, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK (2017). Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma Manag, 4(1), 13-37.
- Clark JI, Wong MKK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S (2016). Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. Clin Genitourin Cancer, 15(1), 31-41.e4.
- Jeter JM, Curiel-Lewandrowski C, Stratton SP, Myrdal PB, Warneke JA, Einspahr JG, Bartels HG, Yozwiak M, Bermudez Y, Hu C, Bartels P, Alberts DS (2015). Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm. Cancer Prev Res (Phila), 9(2), 128-34.
- Fabian CJ, Meyskens FL Jr, Bajorin DF, George TJ Jr, Jeter JM, Khan S, Tyne CA, William WN Jr (2015). Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations From the American Society of Clinical Oncology Cancer Prevention Workforce Pipeline Work Group. J Clin Oncol, 34(2), 186-93.
- Daly MB, Dresher CW, Yates MS, Jeter JM, Karlan BY, Alberts DS, Lu KH (2015). Salpingectomy as a means to reduce ovarian cancer risk. Cancer Prev Res (Phila), 8(5), 342-8.
- Acharya UH, Jeter JM (2013). Use of ipilimumab in the treatment of melanoma. Clin Pharmacol, 5(Suppl 1), 21-7.
- Nelson-Moseke AC, Jeter JM, Cui H, Roe DJ, Chambers SK, Laukaitis CM (2012). An unusual BRCA mutation distribution in a high risk cancer genetics clinic. Fam Cancer, 12(1), 83-7.
- Jeter JM, Alberts DS (2012). Difluoromethylornithine: the proof is in the polyamines. Cancer Prev Res (Phila), 5(12), 1341-4.
- Jeter JM, Han J, Martinez ME, Alberts DS, Qureshi AA, Feskanich D (2012). Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' Health Study. Cancer Causes Control, 23(9), 1451-61.
- Mukherjee B, Delancey JO, Raskin L, Everett J, Jeter J, Begg CB, Orlow I, Berwick M, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Culver HA, Rosso S, Zanetti R, Kanetsky PA, From L, Gruber SB, GEM Study Investigators (2012). Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers. J Natl Cancer Inst, 104(12), 953-6.
- Jeter JM, Cranmer LD, Hersh EM (2012). Ipilimumab pharmacotherapy in patients with metastatic melanoma. Clin Med Insights Oncol, 6, 275-86.
- Jeter JM, Bonner JD, Johnson TM, Gruber SB (2011). Nonsteroidal anti-inflammatory drugs and risk of melanoma. J Skin Cancer, 2011, 598571.
- Rubenstein JH, Waljee AK, Jeter JM, Velayos FS, Ladabaum U, Higgins PD (2009). Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. Am J Gastroenterol, 104(9), 2222-32.
- Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS (2008). Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med, 121(6), 475-483.e3.
- Jeter JM, Kohlmann W, Gruber SB (2006). Genetics of colorectal cancer. Oncology (Williston Park), 20(3), 269-76; discussion 285-6, 288-9.
- Harris RE, Jeter J, Chan P, Higgins P, Kong FM, Fazel R, Bramson C, Gillespie B (2005). Using acupressure to modify alertness in the classroom: a single-blinded, randomized, cross-over trial. J Altern Complement Med, 11(4), 673-9.
Review
- Khan A, Rogers CR, Kennedy CD, Lopez A, Jeter J (2021). Genetic Evaluation for Hereditary Cancer Syndromes Among African Americans: A Critical Review. [Review]. Oncologist, 27(4), 285-291.
- Pauley K, Khan A, Kohlmann W, Jeter J (2022). Considerations for Germline Testing in Melanoma: Updates in Behavioral Change and Pancreatic Surveillance for Carriers of CDKN2A Pathogenic Variants. [Review]. Front Oncol, 12, 837057.
- Vagher J, Gammon A, Kohlmann W, Jeter J (2022). Non-Melanoma Skin Cancers and Other Cutaneous Manifestations in Bone Marrow Failure Syndromes and Rare DNA Repair Disorders. [Review]. Front Oncol, 12, 837059.
Conference Proceedings
Letter
- Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, Jeter J, Abraham I (2019). Response to Yang, Shi, Wang et al. [Letter to the editor]. J Natl Cancer Inst, 112(4), 428.
- Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, Jeter J, Abraham I (2018). Response to Katona et al. [Letter to the editor]. J Natl Cancer Inst, 111(5), 524-525.
- Cranmer LD, Jeter JM, Morgan SS, Hersh EM, Stea B (2010). Whole-brain radiation therapy in melanoma: an open question. [Letter to the editor]. Lancet Oncol, 11(1), 13; author reply 13-4.
Abstract
- Amanda Gammon, Ambreen Khan, Joanne M Jeter (2021). Evaluation of cohort diversity in development and validation studies of hereditary cancer genetic risk assessment models. [Abstract].